715 related articles for article (PubMed ID: 28619436)
21. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
22. [Clinical, radiographic, prognostic and therapeutic aspects of demelinating disease with tumefactive demyelinating lesions].
Launay M; Lebrun C; Giordana E; Chanalet S; Thomas P
Rev Neurol (Paris); 2011 Jan; 167(1):14-22. PubMed ID: 20739040
[TBL] [Abstract][Full Text] [Related]
23. Tumefactive Demyelination Appearing as Multiple Cystic Brain Lesions.
Wynne D; Hung Ho BK; Han TF
World Neurosurg; 2021 Sep; 153():6-8. PubMed ID: 34129977
[TBL] [Abstract][Full Text] [Related]
24. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
Evangelopoulos ME; Koutoulidis V; Andreadou E; Evangelopoulos DS; Kilidireas C
Int J Neurosci; 2016 Dec; 126(12):1097-102. PubMed ID: 26727713
[TBL] [Abstract][Full Text] [Related]
25. Frontal Tumefactive Demyelinating Lesion Mimicking Glioblastoma Differentiated by Methionine Positron Emission Tomography.
Yasuda S; Yano H; Kimura A; Suzui N; Nakayama N; Shinoda J; Iwama T
World Neurosurg; 2018 Nov; 119():244-248. PubMed ID: 30114544
[TBL] [Abstract][Full Text] [Related]
26. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Frederick MC; Cameron MH
Curr Neurol Neurosci Rep; 2016 Mar; 16(3):26. PubMed ID: 26847090
[TBL] [Abstract][Full Text] [Related]
27. A challenging diagnosis of late-onset tumefactive multiple sclerosis associated to cervicodorsal syringomyelia: doubtful CT, MRI, and bioptic findings: Case report and literature review.
Conforti R; Capasso R; Galasso R; Cirillo M; Taglialatela G; Galasso L
Medicine (Baltimore); 2016 Sep; 95(36):e4585. PubMed ID: 27603348
[TBL] [Abstract][Full Text] [Related]
28. Tumefactive Demyelinating Lesions and Pregnancy.
Plantone D; Piantadosi C; Ruggieri S; Anelli V; Koudriavtseva T
Neurol India; 2019; 67(6):1519-1521. PubMed ID: 31857550
[TBL] [Abstract][Full Text] [Related]
29. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
Front Immunol; 2020; 11():668. PubMed ID: 32431694
[TBL] [Abstract][Full Text] [Related]
30. Relapsing Tumefactive Demyelination: A Case Report.
Omerhodžić I; Džurlić A; Lisica D; Mahmutbegović N; Nikšić M; Bilalović N; Suljić E
Acta Med Acad; 2018 Nov; 47(2):193-198. PubMed ID: 30585071
[TBL] [Abstract][Full Text] [Related]
31. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
32. Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Boudot de la Motte M; Louapre C; Bertrand A; Reach P; Lubetzki C; Papeix C; Maillart E
Mult Scler; 2017 Apr; 23(4):614-616. PubMed ID: 28273764
[TBL] [Abstract][Full Text] [Related]
33. Tumefactive demyelinating lesions versus CNS neoplasms, a comparative study.
Chew SH; Achmad Sankala HB; Chew E; Md Arif MHB; Mohd Zain NR; Hashim H; Koya Kutty SB; Chee YC; Mohd Saleh NB; Ong BH; Viswanathan S
Mult Scler Relat Disord; 2023 Nov; 79():104992. PubMed ID: 37717306
[TBL] [Abstract][Full Text] [Related]
34. Tumefactive Multiple Sclerosis Masquerading as High Grade Glioma.
Lin M; Reid P; Bakhsheshian J
World Neurosurg; 2018 Apr; 112():37-38. PubMed ID: 29331745
[TBL] [Abstract][Full Text] [Related]
35. [A case of multiple sclerosis with a tumefactive lesion during long-term treatment with fingolimod, leading to decompressive craniotomy].
Shiraishi W; Miyata T; Matsuyoshi A; Yamada Y; Hatano T; Hashimoto T
Rinsho Shinkeigaku; 2023 Jan; 63(1):37-44. PubMed ID: 36567105
[TBL] [Abstract][Full Text] [Related]
36. Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.
Vakrakou AG; Brinia ME; Svolaki I; Argyrakos T; Stefanis L; Kilidireas C
Front Neurol; 2022; 13():868525. PubMed ID: 35418930
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
38. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
[TBL] [Abstract][Full Text] [Related]
39. Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.
Kiriyama T; Kataoka H; Taoka T; Tonomura Y; Terashima M; Morikawa M; Tanizawa E; Kawahara M; Furiya Y; Sugie K; Kichikawa K; Ueno S
J Neuroimaging; 2011 Apr; 21(2):e69-77. PubMed ID: 20572907
[TBL] [Abstract][Full Text] [Related]
40. Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome.
Ekmekci O; Eraslan C
Case Rep Neurol Med; 2018; 2018():8409247. PubMed ID: 30622825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
